X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2461) 2461
Book Review (508) 508
Newspaper Article (331) 331
Publication (153) 153
Conference Proceeding (49) 49
Magazine Article (32) 32
Trade Publication Article (26) 26
Book / eBook (12) 12
Book Chapter (11) 11
Dissertation (10) 10
Web Resource (10) 10
Newsletter (4) 4
Data Set (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
hypoglycemia (2033) 2033
index medicus (1675) 1675
humans (1603) 1603
diabetes (1585) 1585
insulin (1104) 1104
female (957) 957
male (909) 909
endocrinology & metabolism (869) 869
glucose (663) 663
middle aged (613) 613
type 2 diabetes (608) 608
adult (557) 557
hypoglycemic agents - therapeutic use (544) 544
diabetes mellitus, type 2 - drug therapy (538) 538
diabetes mellitus (517) 517
aged (483) 483
glycemic control (462) 462
patients (392) 392
risk factors (373) 373
mellitus (359) 359
type 1 diabetes (359) 359
hyperglycemia (347) 347
hypoglycemia - chemically induced (346) 346
insulin - therapeutic use (343) 343
diabetes therapy (333) 333
care and treatment (330) 330
hypoglycemic agents - administration & dosage (317) 317
analysis (315) 315
research (304) 304
hypoglycemic agents - adverse effects (303) 303
management (303) 303
diabetes mellitus, type 1 - drug therapy (292) 292
medicine, general & internal (286) 286
adolescent (281) 281
mortality (279) 279
insulin - administration & dosage (270) 270
hypoglycemia - prevention & control (263) 263
hypoglycemia - epidemiology (261) 261
health aspects (260) 260
quality of life (260) 260
blood glucose - metabolism (250) 250
complications (245) 245
studies (244) 244
diabetes mellitus, type 2 - blood (240) 240
internal medicine (235) 235
diabetes mellitus, type 1 - blood (232) 232
medicine & public health (232) 232
risk (230) 230
therapy (221) 221
treatment outcome (220) 220
children (217) 217
child (209) 209
retrospective studies (209) 209
blood glucose - analysis (201) 201
hypoglycaemia (200) 200
clinical trials (193) 193
blood sugar (191) 191
drug therapy (188) 188
glycated hemoglobin a - analysis (187) 187
insulin - adverse effects (185) 185
diabetics (181) 181
glycated hemoglobin a - metabolism (177) 177
severe hypoglycemia (174) 174
prevalence (172) 172
health care sciences & services (171) 171
endocrinology (168) 168
cost-benefit analysis (166) 166
hypoglycemic agents - economics (165) 165
hypoglycemia - etiology (164) 164
medicine (164) 164
young adult (164) 164
pediatrics (161) 161
type 2 diabetes mellitus (160) 160
adults (159) 159
abridged index medicus (158) 158
quality-of-life (155) 155
diabetes mellitus, type 2 - economics (153) 153
diabetes mellitus, type 2 - complications (149) 149
metformin (149) 149
pharmacology & pharmacy (148) 148
association (144) 144
glycosylated hemoglobin (144) 144
medical research (142) 142
aged, 80 and over (137) 137
blood glucose - drug effects (135) 135
dextrose (134) 134
hospitals (132) 132
hemoglobin (130) 130
diagnosis (129) 129
impact (129) 129
adolescents (128) 128
insulin glargine (127) 127
usage (127) 127
hypoglycemia - economics (126) 126
population (126) 126
care (124) 124
hypoglycemia - blood (120) 120
animals (118) 118
original research (118) 118
original (117) 117
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2840) 2840
German (16) 16
Spanish (14) 14
French (12) 12
Korean (3) 3
Portuguese (3) 3
Turkish (3) 3
Czech (1) 1
Danish (1) 1
Slovak (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 12/2017, Volume 19, Issue 12, pp. 1688 - 1697
Aims: To estimate the long-term cost-effectiveness of exenatide twice daily vs insulin glargine once daily as add-on therapy to oral antidiabetic agents (OADs)... 
pharmaco‐economics | antidiabetic drug | cost‐effectiveness | type 2 diabetes | insulin therapy | exenatide | cost-effectiveness | pharmaco-economics | METFORMIN | RISK-FACTORS | CARDIOVASCULAR OUTCOMES | RETROSPECTIVE COHORT | MELLITUS | MODEL | ADHERENCE | ENDOCRINOLOGY & METABOLISM | LIFETIME HEALTH OUTCOMES | WEIGHT-GAIN | UTILITY | Hypoglycemia - epidemiology | Hypoglycemia - therapy | Hypoglycemic Agents - economics | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Diabetic Cardiomyopathies - economics | Models, Economic | Peptides - administration & dosage | Incidence | Cardiovascular Diseases - complications | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Diabetic Angiopathies - prevention & control | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Diabetic Angiopathies - economics | Direct Service Costs | Administration, Oral | Venoms - adverse effects | Hyperglycemia - economics | Drug Therapy, Combination - economics | Diabetic Angiopathies - therapy | Diabetic Cardiomyopathies - epidemiology | Venoms - therapeutic use | Quality of Life | Hyperglycemia - epidemiology | Hypoglycemic Agents - adverse effects | Incretins - administration & dosage | Cardiovascular Diseases - therapy | Diabetes Mellitus, Type 2 - economics | Hypoglycemia - prevention & control | Insulin Glargine - administration & dosage | Drug Therapy, Combination - adverse effects | Peptides - economics | Venoms - administration & dosage | Diabetic Cardiomyopathies - prevention & control | Diabetic Cardiomyopathies - therapy | Hypoglycemia - economics | Diabetes Mellitus, Type 2 - complications | Cardiovascular Diseases - economics | Insulin Glargine - adverse effects | Drug Administration Schedule | Venoms - economics | Insulin Glargine - economics | Insulin Glargine - therapeutic use | China - epidemiology | Randomized Controlled Trials as Topic | Diabetes Mellitus, Type 2 - blood | Cost-Benefit Analysis | Incretins - adverse effects | Diabetic Angiopathies - epidemiology | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Hyperglycemia - therapy | Peptides - adverse effects | Peptides - therapeutic use | Incretins - economics | Type 2 diabetes | Insulin | Analysis | Diabetes therapy | Literature reviews | Databases | Diabetes mellitus | Clinical trials | Diabetes | Cost analysis | Hypoglycemia | Patients | Diabetes mellitus (non-insulin dependent) | Index Medicus
Journal Article
Diabetic Medicine, ISSN 0742-3071, 04/2016, Volume 33, Issue 4, pp. 471 - 477
The study is unique in reporting resource use associated with severe hypoglycaemia from a randomized controlled trial setting, because resource use has... 
GLYCEMIC CONTROL | 26-WEEK | GLARGINE | NAIVE PATIENTS | ENDOCRINOLOGY & METABOLISM | NON-INFERIORITY TRIAL | OPEN-LABEL | TO-TARGET TRIAL | BASAL-BOLUS TREATMENT | TYPE-2 | DEGLUDEC/INSULIN ASPART | Hypoglycemia - therapy | Hypoglycemic Agents - economics | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Insulin Detemir - therapeutic use | Insulin Detemir - economics | Clinical Trials, Phase III as Topic | Hypoglycemic Agents - administration & dosage | Hypoglycemic Agents - therapeutic use | Sitagliptin Phosphate - administration & dosage | Costs and Cost Analysis | Administration, Oral | Drug Therapy, Combination - economics | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Insulin Aspart - economics | Insulin, Long-Acting - adverse effects | Insulin, Long-Acting - administration & dosage | Diabetes Mellitus, Type 1 - economics | Diabetes Mellitus, Type 1 - blood | Insulin, Long-Acting - therapeutic use | Hypoglycemic Agents - adverse effects | Insulin Aspart - adverse effects | Cohort Studies | Insulin Aspart - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Diabetes Mellitus, Type 2 - economics | Insulin, Long-Acting - economics | Dipeptidyl-Peptidase IV Inhibitors - economics | Insulin Glargine - administration & dosage | Drug Therapy, Combination - adverse effects | Insulin Aspart - administration & dosage | Insulin Detemir - administration & dosage | Insulin Detemir - adverse effects | Hypoglycemia - physiopathology | Adult | Hypoglycemia - economics | Hypoglycemia - chemically induced | Severity of Illness Index | Insulin Glargine - adverse effects | Drug Administration Schedule | Insulin Glargine - economics | Insulin Glargine - therapeutic use | Sitagliptin Phosphate - economics | Diabetes Mellitus, Type 1 - drug therapy | Diabetes Mellitus, Type 2 - blood | Health Care Costs | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Drug Combinations | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Adults | Type 1 diabetes | Insulin | Analysis | Emergency medical care | Diabetes | Hypoglycemia | Index Medicus | Complications | Research
Journal Article
Value in Health, ISSN 1098-3015, 2011, Volume 14, Issue 5, pp. 665 - 671
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2016, Volume 11, Issue 9, pp. e0162951 - e0162951
The costs of drug-induced hypoglycemia are a critical but often neglected component of value-based arguments to reduce tight glycemic control in older adults... 
Insulin - economics | Outcome Assessment (Health Care) - methods | United States - epidemiology | Hypoglycemia - epidemiology | Metformin - therapeutic use | Hypoglycemic Agents - economics | Humans | Diabetes Mellitus, Type 2 - economics | Models, Economic | Metformin - adverse effects | Sulfonylurea Compounds - economics | Incidence | Metformin - economics | Thiazolidinediones - therapeutic use | Canada - epidemiology | Aged, 80 and over | Hypoglycemia - economics | Hypoglycemia - chemically induced | Hypoglycemic Agents - therapeutic use | Quality-Adjusted Life Years | Sulfonylurea Compounds - therapeutic use | Thiazolidinediones - economics | Sulfonylurea Compounds - adverse effects | Thiazolidinediones - adverse effects | Outcome Assessment (Health Care) - economics | Cost-Benefit Analysis | Aged | Decision Trees | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Monte Carlo Method | Insulin - therapeutic use | Type 2 diabetes | Prevention | Glucagon | Economic aspects | Glucose | Comparative analysis | Medical economics | Dextrose | Diabetes therapy | Health care | Elderly people | Economic analysis | Costs | Systematic review | Emergency medical care | Body mass index | Older people | Population | Diabetes mellitus (non-insulin dependent) | Public health | Diabetes mellitus | Hypoglycemia | Decision analysis | Insulin | Patients | Cost control | Quality of life | Government programs | Pharmacy | Adults | Diabetes | Metformin | Cost analysis | Thiazolidinediones | Age groups | Index Medicus
Journal Article
Diabetic Medicine, ISSN 0742-3071, 07/2015, Volume 32, Issue 7, pp. 890 - 898
Dapagliflozin is a selective sodium–glucose co–transporter–2 (SGLT‐2) inhibitor licensed in the European Union (EU) for use in people with Type 2 diabetes... 
HEALTH-RELATED UTILITY | INSULIN | THERAPY | MODELS | SAXAGLIPTIN | ENDOCRINOLOGY & METABOLISM | HYPOGLYCEMIA | WEIGHT-GAIN | COMPLICATIONS | INADEQUATE GLYCEMIC CONTROL | STRATEGIES | Hypoglycemia - therapy | Hypoglycemic Agents - economics | Humans | Middle Aged | Male | Diabetes Complications - therapy | Weight Loss - drug effects | Metformin - adverse effects | Metformin - economics | Sodium-Glucose Transport Proteins - metabolism | Benzhydryl Compounds - therapeutic use | Glucosides - adverse effects | Hypoglycemic Agents - therapeutic use | Quality-Adjusted Life Years | Hyperglycemia - prevention & control | Hyperglycemia - economics | Diabetes Complications - economics | Drug Therapy, Combination - economics | Overweight - prevention & control | Overweight - therapy | Glucosides - economics | Hypoglycemic Agents - adverse effects | Cohort Studies | Metformin - therapeutic use | Diabetes Mellitus, Type 2 - economics | Risk | Diabetes Mellitus, Type 2 - metabolism | Sulfonylurea Compounds - economics | Hypoglycemia - prevention & control | Drug Therapy, Combination - adverse effects | Benzhydryl Compounds - adverse effects | Overweight - epidemiology | Diabetes Complications - epidemiology | Female | Glucosides - therapeutic use | Hypoglycemia - economics | Hypoglycemia - chemically induced | Overweight - economics | Diabetes Mellitus, Type 2 - complications | Drug Resistance | Diabetes Complications - prevention & control | Sulfonylurea Compounds - therapeutic use | Benzhydryl Compounds - economics | Sulfonylurea Compounds - adverse effects | Health Care Costs | Cost-Benefit Analysis | Sodium-Glucose Transport Proteins - antagonists & inhibitors | Diabetes Mellitus, Type 2 - drug therapy | Hyperglycemia - therapy | United Kingdom - epidemiology | Type 2 diabetes | Analysis | Development and progression | Hypoglycemic agents | Glucose | Dextrose | Diabetes therapy | Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2018, Volume 20, Issue 8, pp. 1921 - 1927
Aims The recent LIRA-SWITCH trial showed that switching from sitagliptin 100 mg to liraglutide 1.8 mg led to statistically significant and clinically relevant... 
cost‐effectiveness | GLP‐1 analogue | type 2 diabetes | incretin therapy | liraglutide, sitagliptin | cost-effectiveness | GLP-1 analogue | liraglutide | VALIDATION | UTILITY VALUES | MELLITUS | MODEL | sitagliptin | DISEASE | ENDOCRINOLOGY & METABOLISM | MULTIFACTORIAL INTERVENTION | COMPLICATIONS | OUTCOMES | Anti-Obesity Agents - economics | Hypoglycemia - therapy | Overweight - complications | Hypoglycemic Agents - economics | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Overweight - drug therapy | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Anti-Obesity Agents - adverse effects | Diabetes Mellitus, Type 2 - economics | Diabetes Complications - therapy | Diabetes Mellitus, Type 2 - metabolism | Models, Economic | Weight Loss - drug effects | Anti-Obesity Agents - therapeutic use | Liraglutide - economics | Dipeptidyl-Peptidase IV Inhibitors - economics | Hypoglycemia - prevention & control | Overweight - metabolism | Glucagon-Like Peptide-1 Receptor - metabolism | Diabetes Complications - epidemiology | Hypoglycemia - economics | Hypoglycemia - chemically induced | Overweight - economics | Diabetes Mellitus, Type 2 - complications | Drug Resistance | Diabetes Complications - prevention & control | Body Mass Index | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Hyperglycemia - economics | Risk Factors | Sitagliptin Phosphate - economics | Diabetes Complications - economics | Health Care Costs | Liraglutide - adverse effects | Cost-Benefit Analysis | Liraglutide - therapeutic use | Quality of Life | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Drug Monitoring | Hyperglycemia - therapy | Hypoglycemic Agents - adverse effects | United Kingdom - epidemiology | Glucagon-Like Peptide-1 Receptor - agonists | Cohort Studies | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Glycosylated hemoglobin | Hypoglycemic agents | Cost benefit analysis | Health aspects | Analysis | Body mass index | Costs | Statistical analysis | Life span | Diabetes mellitus | Hemoglobin | Diabetes | Diabetes mellitus (non-insulin dependent) | Patients | Clinical outcomes | Index Medicus
Journal Article
Journal Article
Nutrition, Metabolism and Cardiovascular Diseases, ISSN 0939-4753, 2016, Volume 27, Issue 3, pp. 209 - 216
Journal Article
Journal Article